Profile data is unavailable for this security.
About the company
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
- Revenue in USD (TTM)23.84m
- Net income in USD-68.83m
- Incorporated2007
- Employees75.00
- LocationAadi Bioscience Inc17383 Sunset Avenue, Suite A250PACIFIC PALISADES 90272United StatesUSA
- Phone+1 (424) 473-8055
- Fax+1 (302) 655-5049
- Websitehttps://aadibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc | 19.01m | -11.30m | 43.68m | 14.00 | -- | 0.9178 | -- | 2.30 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Bright Green Corp | 0.00 | -13.13m | 43.74m | 5.00 | -- | 3.88 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 44.22m | 176.00 | -- | 2.86 | -- | 1.53 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 45.34m | 31.00 | -- | 2.54 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 46.62m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 46.72m | 82.00 | -- | 0.4705 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 46.90m | 75.00 | -- | 0.5185 | -- | 1.97 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 47.48m | 29.00 | -- | 3.39 | -- | 860.40 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Clene Inc. | 620.00k | -48.81m | 47.52m | 82.00 | -- | 11.14 | -- | 76.65 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Benson Hill Inc | 359.83m | -132.72m | 47.89m | 270.00 | -- | 0.7116 | -- | 0.1331 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Journey Medical Corp | 79.18m | -3.85m | 48.21m | 58.00 | -- | 3.28 | -- | 0.6088 | -0.3502 | -0.3502 | 4.19 | 1.05 | 0.8701 | 2.19 | 3.65 | 1,365,190.00 | -4.23 | -- | -10.51 | -- | 66.33 | -- | -4.87 | -- | 1.10 | 0.6863 | 0.4641 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Dyadic International Inc | 2.26m | -7.85m | 48.24m | 7.00 | -- | 10.66 | -- | 21.39 | -0.2724 | -0.2724 | 0.0783 | 0.1547 | 0.1769 | -- | 4.51 | 322,197.20 | -61.58 | -36.82 | -73.50 | -39.85 | 38.24 | 22.47 | -348.00 | -410.16 | -- | -- | 0.5634 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -6.00m | 48.31m | 4.00 | -- | 1.37 | -- | -- | -0.4155 | -0.4155 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -15.24 | -27.78 | -15.81 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 48.81m | 23.00 | -- | -- | -- | 17.33 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Inotiv Inc | 585.17m | -33.21m | 49.78m | 1.96k | -- | 0.1958 | 2.27 | 0.0851 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
Data as of May 20 2024. Currency figures normalised to Aadi Bioscience Inc's reporting currency: US Dollar USD
36.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 2.85m | 11.61% |
| Acuta Capital Partners LLCas of 31 Mar 2024 | 1.85m | 7.53% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 952.98k | 3.88% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 843.94k | 3.44% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 543.72k | 2.21% |
| Citadel Advisors LLCas of 31 Mar 2024 | 486.41k | 1.98% |
| Geode Capital Management LLCas of 31 Mar 2024 | 399.23k | 1.63% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 375.15k | 1.53% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 354.19k | 1.44% |
| Acuitas Investments LLCas of 31 Mar 2024 | 318.14k | 1.30% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
